You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Ovarian cancer

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

  • Technology appraisal guidance
  • Reference number: TA673
  • Published:  17 February 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Invitation to participate
  3. Final draft guidance
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 141 KB)

    Published:
    17 February 2021
  • Register of interests (PDF 162 KB)

    Published:
    26 February 2021

Invitation to participate

  • Final scope (PDF 201 KB)

    Published:
    11 March 2020
  • Final stakeholder list (PDF 186 KB)

    Published:
    11 March 2020
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 247 KB)

    Published:
    20 April 2020
  • Equality impact assessment (Scoping) (PDF 124 KB)

    Published:
    20 April 2020

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 271 KB)

    Published:
    15 January 2021
  • Final appraisal document - Managed Access Agreement (PDF 387 KB)

    Published:
    15 January 2021
  • Committee papers (PDF 6.58 MB)

    Published:
    15 January 2021
  • Public committee slides (PDF 1.38 MB)

    Published:
    15 January 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft scope post referral (PDF 211 KB)

    Published:
    19 November 2019
  • Draft matrix post referral (PDF 187 KB)

    Published:
    19 November 2019
Back to top